Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382502401> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4382502401 endingPage "420" @default.
- W4382502401 startingPage "410" @default.
- W4382502401 abstract "Tegoprazan is a differentiated gastric acid-pump blocker and belongs to a class of potassium-competitive acid secretion blockers. An orally disintegrating tablet (ODT) of tegoprazan was developed to improve patient compliance. The purpose of this study was to compare pharmacokinetics (PK) and safety profiles between the conventional tablet (as the reference drug) and the ODT (as the test drug) of 50 mg tegoprazan in healthy Korean subjects.An open-label, randomized, single-dose, 6-sequence, 3-period crossover study was conducted in 48 healthy subjects. All subjects received a single oral dose of tegoprazan 50 mg tablet with water, tegoprazan 50 mg ODT with water, and tegoprazan 50 mg ODT without water. Serial blood samples were collected up to 48 hours after dosing. Plasma concentrations of tegoprazan and its metabolite M1 were measured by LC-MS/MS, and PK parameters were calculated with a non-compartmental method. Safety was evaluated by means of assessed adverse events, physical examinations, laboratory test results as well as measurements of vital signs and ECG throughout the study.A total of 47 subjects completed the study. The 90% confidence intervals of the geometric mean ratios for AUCt, Cmax, and AUCinf of tegoprazan were 0.8873 - 0.9729, 0.8865 - 1.0569, and 0.8835 - 0.9695 for the test drug with water to the reference drug and 0.9169 - 1.0127, 0.9569 - 1.1276, and 0.9166 - 1.0131 for the test drug without water to the reference drug, respectively. There were no serious adverse events, and all adverse events were mild.The PK profiles of tegoprazan were equivalent between the conventional tablet and ODT with or without water. There was no significant difference in the safety profiles. Therefore, the novel ODT of tegoprazan that can be taken without water may improve compliance among patients with acid-related diseases." @default.
- W4382502401 created "2023-06-30" @default.
- W4382502401 creator A5013953358 @default.
- W4382502401 creator A5014037760 @default.
- W4382502401 creator A5026180456 @default.
- W4382502401 creator A5027946569 @default.
- W4382502401 creator A5074208108 @default.
- W4382502401 creator A5079217765 @default.
- W4382502401 creator A5081300522 @default.
- W4382502401 date "2023-09-01" @default.
- W4382502401 modified "2023-09-23" @default.
- W4382502401 title "Evaluation of the comparative pharmacokinetic properties of a new orally disintegrating tablet of tegoprazan in healthy Korean subjects" @default.
- W4382502401 doi "https://doi.org/10.5414/cp204378" @default.
- W4382502401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37382330" @default.
- W4382502401 hasPublicationYear "2023" @default.
- W4382502401 type Work @default.
- W4382502401 citedByCount "0" @default.
- W4382502401 crossrefType "journal-article" @default.
- W4382502401 hasAuthorship W4382502401A5013953358 @default.
- W4382502401 hasAuthorship W4382502401A5014037760 @default.
- W4382502401 hasAuthorship W4382502401A5026180456 @default.
- W4382502401 hasAuthorship W4382502401A5027946569 @default.
- W4382502401 hasAuthorship W4382502401A5074208108 @default.
- W4382502401 hasAuthorship W4382502401A5079217765 @default.
- W4382502401 hasAuthorship W4382502401A5081300522 @default.
- W4382502401 hasConcept C112705442 @default.
- W4382502401 hasConcept C126322002 @default.
- W4382502401 hasConcept C142724271 @default.
- W4382502401 hasConcept C149151106 @default.
- W4382502401 hasConcept C197934379 @default.
- W4382502401 hasConcept C204787440 @default.
- W4382502401 hasConcept C22979827 @default.
- W4382502401 hasConcept C27081682 @default.
- W4382502401 hasConcept C2777056448 @default.
- W4382502401 hasConcept C2777288759 @default.
- W4382502401 hasConcept C2777477808 @default.
- W4382502401 hasConcept C2780035454 @default.
- W4382502401 hasConcept C71924100 @default.
- W4382502401 hasConcept C87813604 @default.
- W4382502401 hasConcept C98274493 @default.
- W4382502401 hasConceptScore W4382502401C112705442 @default.
- W4382502401 hasConceptScore W4382502401C126322002 @default.
- W4382502401 hasConceptScore W4382502401C142724271 @default.
- W4382502401 hasConceptScore W4382502401C149151106 @default.
- W4382502401 hasConceptScore W4382502401C197934379 @default.
- W4382502401 hasConceptScore W4382502401C204787440 @default.
- W4382502401 hasConceptScore W4382502401C22979827 @default.
- W4382502401 hasConceptScore W4382502401C27081682 @default.
- W4382502401 hasConceptScore W4382502401C2777056448 @default.
- W4382502401 hasConceptScore W4382502401C2777288759 @default.
- W4382502401 hasConceptScore W4382502401C2777477808 @default.
- W4382502401 hasConceptScore W4382502401C2780035454 @default.
- W4382502401 hasConceptScore W4382502401C71924100 @default.
- W4382502401 hasConceptScore W4382502401C87813604 @default.
- W4382502401 hasConceptScore W4382502401C98274493 @default.
- W4382502401 hasIssue "09" @default.
- W4382502401 hasLocation W43825024011 @default.
- W4382502401 hasLocation W43825024012 @default.
- W4382502401 hasOpenAccess W4382502401 @default.
- W4382502401 hasPrimaryLocation W43825024011 @default.
- W4382502401 hasRelatedWork W1998356222 @default.
- W4382502401 hasRelatedWork W2030336508 @default.
- W4382502401 hasRelatedWork W2040155790 @default.
- W4382502401 hasRelatedWork W2051764329 @default.
- W4382502401 hasRelatedWork W2056938528 @default.
- W4382502401 hasRelatedWork W2080913083 @default.
- W4382502401 hasRelatedWork W2151580563 @default.
- W4382502401 hasRelatedWork W2316142895 @default.
- W4382502401 hasRelatedWork W2321335410 @default.
- W4382502401 hasRelatedWork W2331297863 @default.
- W4382502401 hasVolume "61" @default.
- W4382502401 isParatext "false" @default.
- W4382502401 isRetracted "false" @default.
- W4382502401 workType "article" @default.